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ttp://dx.doi.org/10.1016/j.ajpath.2015.01.014We previously found loss of forkhead box A1 (FOXA1) expression to be associated with aggressive urothelial
carcinoma of the bladder, as well as increased tumor proliferation and invasion. These initial ﬁndings were
substantiated by The Cancer Genome Atlas, which identiﬁed FOXA1mutations in a subset of bladder cancers.
However, the prognostic signiﬁcance of FOXA1 inactivation and the effect of FOXA1 loss on urothelial
differentiation remain unknown. Application of a univariate analysis (log-rank) and a multivariate Cox
proportional hazards regressionmodel revealed that loss of FOXA1 expression is an independent predictor of
decreased overall survival. An ubiquitin Cre-driven system ablating Foxa1 expression in urothelium of adult
mice resulted in sex-speciﬁc histologic alterations, with male mice developing urothelial hyperplasia and
femalemice developing keratinizing squamousmetaplasia. Microarray analysis conﬁrmed these ﬁndings and
revealed a signiﬁcant increase in cytokeratin 14 expression in the urothelium of the female Foxa1 knockout
mouse and an increase in the expression of a number of genes normally associated with keratinocyte dif-
ferentiation. IHC conﬁrmed increased cytokeratin 14 expression in female bladders and additionally
revealed enrichment of cytokeratin 14epositive basal cells in the hyperplastic urothelial mucosa in male
Foxa1 knockout mice. Analysis of human tumor specimens conﬁrmed a signiﬁcant relationship between loss
of FOXA1 and increased cytokeratin 14 expression. (Am J Pathol 2015, 185: 1385e1395; http://dx.doi.org/
10.1016/j.ajpath.2015.01.014)Supported by National Cancer Institute grants 1K99CA172122 and
R00CA172122 (D.J.D.) and 1P01CA165980-01 (X.-R.W.); a Young
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R01-DK055748-15 (R.J.M.); the Vanderbilt Medical Scholars Program and
NIH CTSA grant TL1 TR000447 (O.L.T.); the National Center for
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development or marketed products to declare.In the United States, there are approximately 73,000 new
cases of urinary bladder cancer (UBC) annually, accounting
for approximately 15,000 deaths.1 Although the incidence is
approximately four times higher in men than in women,
women often present with more advanced disease and have
worse clinical outcomes.2 Approximately 90% of UBCs are
urothelial carcinomas (UCs), with squamous cell carci-
nomas (SCCs) and adenocarcinomas largely comprising the
remainder. Management of nonemuscle-invasive UBC
[American Joint Committee on Cancer (AJCC) tumor stages
pTa, pTis, and pT1] involves transurethral resection with orstigative Pathology.
.
Reddy et alwithout adjuvant intravesical therapy followed by careful
surveillance.3 For muscle-invasive UBC (AJCC tumor stage
pT2 or higher), radical cystectomy with or without neo-
adjuvant chemotherapy is the cornerstone of management.4
Despite these aggressive measures, the disease recurs in
approximately 50% of patients, and the 5-year overall sur-
vival rate is only 6% for patients who develop or present
with distant metastatic disease.5 Therefore, there is a sig-
niﬁcant need for novel approaches geared toward identi-
fying those patients most at risk for disease progression or
death, as well as identifying pathways that can act as targets
for novel therapeutics.
Interestingly, a signiﬁcant subset (approximately 40%) of
UC exhibits squamous differentiation, with some cases
showing focal keratinizing squamous metaplasia (KSM) and
others developing into predominant or pure SCC.Whereas pure
SCC of the bladder has a worse prognosis than UC,6 whether
the presence of squamous differentiation in the background of
UC is indeed a poor prognostic indicator is still controversial.
Both SCC and UC with squamous differentiation may be
associated with resistance to systemic chemotherapy,7 which
could account for poor overall outcomes. Currently, there is no
consensus regarding the extent of squamous differentiation that
confers increased clinical risk.
Forkhead box A1 (FOXA1) is a member of the forkhead
box A subfamily of transcription factors, which includes
genes encoding for FOXA1, FOXA2, and FOXA3. FOXA1
protein is expressed in the developing and adult urothelium,
whereas FOXA2 protein expression is restricted to early
bladder development, where it appears to play a signiﬁcant
role in urothelial development.8,9
We originally reported that loss of FOXA1 expression is
associated with high-grade, late-stage UC, as well as
increased tumor cell proliferation and invasion.10 Further-
more, we found that FOXA2 is expressed in a subset of UC,
potentially recapitulating early bladder development.
Recently, the Cancer Genome Atlas provided a comprehen-
sive molecular characterization of muscle-invasive UBC.11
In addition to conﬁrming our initial reports regarding the
loss of FOXA1 in human UBC, this work extended our
original analysis by revealing that FOXA1 is mutated in 5%
of UBC. In addition, another recent report found that absence
of FOXA1 expression was associated with a basal molecular
phenotype that expresses markers associated with squamous
differentiation and is more common in female UBC.12
Therefore, in addition to other molecular factors, both
FOXA1 and FOXA2 appear to play a central role in bladder
development, urothelial differentiation, and malignant pro-
gression.9e11 However, the prognostic and clinical signiﬁ-
cance of FOXA1 loss in human UC is currently unknown. To
address this issue, we used a tissue microarray (TMA) con-
sisting of>600 bladder tissue samples from 301 patients who
underwent cystectomy for UBC to explore the association of
FOXA1 loss with clinical outcome in these patients.
Although FOXA1 loss is associated with both UC, UC with
squamous differentiation, and pure SCC of the urinary1386bladder in humans, it is unclear whether inactivation of
FOXA1 itself is sufﬁcient to drive histologic alterations and/
or tumor progression. Therefore, we used an inducible sys-
tem to genetically ablate Foxa1 in the adult murine urothe-
lium, which enabled us to directly address this question.
Materials and Methods
Ethics Statement
Human UBC samples were collected by the Translational
Pathology Shared Resource, a core facility of the Vanderbilt-
Ingram Cancer Center, and later deidentiﬁed for testing and
analysis. Clinical, pathological, and follow-up data were
collected via review of medical records and extracted to the
Research Electronic Data Capture database hosted at Van-
derbilt University.13 This project was approved by the Insti-
tutional Review Board at Vanderbilt University. All animal
work was approved by and performed in accordance with
Institutional Animal Care and Use Committee guidelines.
Human Tissue Samples and Generation of TMAs
TMAs were generated using 657 bladder tissue cores from 301
patients who underwent cystectomy for UC or SCC of the
bladder between January 2000 and May 2010. All patients
underwent radical cystectomy, bilateral pelvic lymphadenec-
tomy, and urinary diversion. Patients were subsequently fol-
lowed up at 3months, 6months, and then at increasing intervals
based on individual surgeons’ practice patterns by physical
examination, laboratory studies, and both chest and abdominal
imaging. Clinicopathologic data were collected and included
patient demographics, such as age at time of surgery, sex, and
comorbidity recorded as age-adjusted Charlson comorbidity
index,14 and tumor characteristics, such as AJCC tumor stage
(seventh edition, 2010 guidelines15) and grade.
The original hematoxylin and eosin (H&E) slides were
reviewed and diagnostic tissue wasmarked for construction of a
TMAusing amanual arrayer (Beecher Instruments, Sun Prairie,
WI). One to three tissue cores (each 1.5 mm) of representative
areas from each of the selected formalin-ﬁxed, parafﬁn-
embedded tissue blocks were used for the array. H&E slides
from the TMAs were prepared, and the histopathological
diagnosis of tissue samples represented on the TMA were
identiﬁed for each patient (wherever available), including
adjacent benign urothelium, noninvasive papillary urothelial
carcinoma (pTa), urothelial carcinoma in situ (pTis), or invasive
urothelial carcinoma (pT1-pT4), and were recorded in a
Research Electronic Data Capture relational database.
IHC Staining and Evaluation
Immunohistochemistry (IHC) was performed on human and
murine samples. Slides were deparafﬁnized and rehydrated
through a series of graded alcohols and washed in deionized
water for 5 minutes. Antigen retrieval was performed byajp.amjpathol.org - The American Journal of Pathology
Table 1 Patient and Tumor Characteristics Included in Tissue
Microarray
Characteristic Finding
Age, years, median (IQR) 67 (59e73)
Sex, no. (%)
Male 239 (79)
Female 62 (21)
Race, no. (%)*
White 279 (93)
Nonwhite 20 (6)
Not reported 2 (1)
Charlson Comorbidity Index, no. (%)
0e1 51 (17)
2e3 124 (41)
>4 126 (42)
T stage, no. (%)
Ta 7 (2)
Tis 38 (13)
T1 41 (14)
T2 98 (32)
T3 83 (28)
T4 34 (11)
N stage, no. (%)
N0 231 (77)
N1 or greater 70 (23)
Grade, no. (%)
Low grade 8 (3)
High grade 293 (97)
*Data on race was self-reported by patients.
IQR, interquartile range.
FOXA1 and Bladder Cancer Prognosisplacing slides in 1% antigen unmasking solution (Vector
Labs, Burlingame, CA) and heating slides for 25 minutes on
high power in a pressure cooker (Cook’s Essentials
CEPC800). Steam was released in short bursts to prevent
boiling and preserve tissue integrity. Slides were cooled to
room temperature and washed 3 times for 10 minutes in
PBS (pH 7.4). All incubations were performed at room
temperature unless otherwise noted. Endogenous peroxi-
dases were blocked by incubation in 1% hydrogen peroxide
in methanol for 20 minutes, and slides were again washed 3
times for 10 minutes in phosphate-buffered saline (PBS).
Sections were incubated in PBS containing horse serum
(Vector Labs) for 30 minutes to reduce nonspeciﬁc antibody
binding and then incubated overnight with primary antibody
at 4C in a humidiﬁed chamber. Antibodies used include
goat polyclonal FOXA1 (1:1000; Santa Cruz Biotech-
nology, Santa Cruz, CA), mouse polyclonal cytokeratin 10
(CK10) (1:200; Dako, Carpinteria, CA), mouse polyclonal
cytokeratin 14 (CK14) (1:200; Dako), and mouse polyclonal
uroplakin III (UPKIII) (1:5000; Fitzgerald, Acton, MA) all
diluted in PBS containing horse serum.
Bromodeoxyuridine (BrdU) staining of mouse speci-
mens was stained by the Vanderbilt Experimental Pathol-
ogy Core. Slides were then washed 3 times for 10 minutes
in PBS and sections were incubated in biotinylated sec-
ondary antibody diluted in PBS containing horse serum
(1:200; Vector Labs) for 1 hour. Speciﬁc antibody binding
was visualized using Vectastain Elite ABC Peroxidase kit
(Vector Labs) according to the manufacturer protocol with
diaminobenzidine substrate buffer as the chromogen
(Thermo Scientiﬁc, Fremont, CA). The intensity and dis-
tribution of immunoreactivity for each TMA core were
scored by a pathologist (J.M.C.) using the Allred scoring
system, where scales of 0 to 3 were used for intensity and
0 to 5 for percentage of positive tumor cells.16 An IHC
index was assigned to each sample by summation of the
intensity score and distribution score.
Statistical Analysis of IHC Scores
For all analyses, replicate IHC scores from cores of the same
pathological stage from the same patient were averaged.
Correlations among IHC scores and tumor stage were
assessed using Spearman rank coefﬁcients. The extended
Mantel-Haenszel test was used to assess correlations between
IHC scores after adjusting for tumor stage. For survival
analysis and correlation analysis comparing clinical tumor
stage with IHC scores, the following exclusion criteria were
applied to the original cohort of 301 tumor samples to reduce
the potential inﬂuence of ﬁeld effect phenomena. For patients
with multiple specimens or different samples from a single
specimen represented on the TMA, the sample of the highest
pathological stage available was used, and the other samples
were excluded. Patient samples recorded as adjacent benign
urothelium (n Z 25) and cores that could not be histologi-
cally assessed (nZ 15) were also excluded.The American Journal of Pathology - ajp.amjpathol.orgPatients with overall tumor stages pT2 or higher were
excluded if invasive tumor was not represented on the TMA
(nZ 17). Because of the low numbers, patients with tumors
of low histological grade (n Z 8) were also excluded from
survival analysis. Two patients had low-grade disease at the
time of cystectomy, but we were not able to assess the tissue
cores included in the TMAs. This resulted in the use of 234
patients available for survival analysis. Overall survival was
deﬁned as the interval from the date of cystectomy to the
date of death from any cause, or patients were censored at
the date of last follow-up.
Univariate analyses were performed using log rank tests
and visualized using Kaplan-Meier survival curves. For
univariate log rank analyses, age was grouped into quartile
distributions, and comorbidity index was grouped into tertile
distributions. Tumor stage was grouped by organ-conﬁned
disease (AJCC tumor stages pTa, pTis, pT1, and pT2),
extravesical disease (pT3 to pT4), and node-positive disease
(any pT or N1 to N2). Variables associated with adverse
prognosis based on previous studies17 and variables with
P < 0.1018 on univariate analysis were included in a multi-
variate analysis using a Cox proportional hazards model.
The extendedMantel-Haenszel test was used to analyze the
correlation between FOXA1 and CK14 expression in human
tissue, independent of tumor stage. Fisher’s exact test was
applied to determine signiﬁcance of observed phenotypes1387
Figure 1 Loss of FOXA1 expression is signiﬁcantly associated with
decreased overall survival in human bladder cancer. Kaplan-Meier survival
curves by FOXA1 expression. Univariate analysis shows loss of FOXA1 is
signiﬁcantly associated with reduced overall survival (P < 0.001). See
Table 2 for multivariate analysis.
Table 2 Multivariate Cox Proportional Hazards Model Predicting
Overall Survival after Radical Cystectomy
Variable
Overall survival
HR (95% CI) P value
Age 0.99 (0.97e1.02) 0.526
Charlson Comorbidity Index 1.25 (1.11e1.40) <0.001
Sex
Male Referent
Female 0.63 (0.41e0.97) 0.037
Tumor stage
Organ-conﬁned disease Referent
Extra-vesical disease 2.00 (1.27e3.15) 0.003
Node-positive disease 3.49 (2.31e5.28) <0.001
Low FOXA1 1.49 (1.04e2.13) 0.028
Reddy et alafter Foxa1 knockout in male and female mice. For all tests,
P< 0.05 was considered statistically signiﬁcant. Stata version
12.0 (Stata Corp., College Station, TX) was used for analysis
of human clinical data and mouse knockout data.
Mouse Breeding Experiments
Foxa1loxp mice have been previously described.19 Globally
inducible Foxa1 knockout was achieved by breeding
B6.Cg-Tg(UBC-Cre/ERT2)1Ejb/j mice (hereafter simply
UBC-Cre/ERT2) to Foxa1loxp/loxp mice, resulting in UBC-
Cre/ERT2/Foxa1loxp/loxp mice, respectively. Once sexually
mature, male and female UBC-Cre/ERT2/Foxa1loxp/loxp
and littermate Foxa1loxp/loxp control mice were injected i.p.
with 1 mg/d of tamoxifen for 5 days and separated into
three groups. The ﬁrst group was euthanized immediately
after 5 days to determine the efﬁcacy of UBC-Cre/ERT2 to
induce ablation of Foxa1 expression. The second and third
groups of mice were euthanized 3 and 6 months after
tamoxifen injection, respectively, to determine the effect of
long-term Foxa1 knockout. All mice were injected with
BrdU before euthanasia. A subset of individual bladders
were dissected and bisected, with one bladder half being
dedicated to formalin ﬁxation and parafﬁn embedding by
standard procedures and the other half being used for
microarray studies (see below).
Gene Expression Studies
Dissected tissue was placed in RNAlater (Qiagen, Venlo,
the Netherlands) to stabilize RNA, and RNA was extracted
using RNEasy (Qiagen) according to the manufacturer’s
instructions. Microarray analysis on RNA extracted from
bladder tissue dissected from control and experimental mice
(four control Foxa1loxp/loxp and three Foxa1 knockout male
mice and four control Foxa1loxp/loxp and six Foxa1 knockout
female mice) was performed using the Mouse Gene 1.0 ST
Array (Affymetrix Corp, Santa Clara, CA) by the Vanderbilt1388Technologies for Advanced Genomics core. The Mouse
Gene 1.0 ST Array contains probes for >28,000 coding
transcripts and approximately 7000 noncoding transcripts,
including 2000 long intergenic noncoding transcripts.
Instrument control and data acquisition were performed
using the Affymetrix GeneChip Command Console. Fold
change was calculated in a log base 2 space, using the
formula Fold ChangeZ2^ðexperimental controlÞ fol-
lowed by inverting and negating ratios <1.0.
To analyze data, we ﬁrst normalized the microarray gene-
expression data and analyzed the RNA abundance between the
Foxa1 knockout mice and the control mice within each sex
using the limma package provided by BioConductor version
2.14 (Fred Hutchinson Cancer Research Center, Seattle, WA).
We then compared the effect of Foxa1 knockout on gene
expression between female and male mice and identiﬁed
differentially expressed genes by sex, as well as those shared
by both sexes. The Benjamini-Hochberg procedure was used
to control the false discovery rate in multiple comparisons.
Differentially expressed genes were prioritized based on the
following criteria: jlogFCj>2 and false discovery ratee
adjusted P< 0.01. All statistical analyses were performed in R
version 3.0.2 (http://www.r-project.org). Data were analyzed
through the use of the Ingenuity Pathway Analysis (IPA;
Qiagen, Redwood City, CA) and were used with permission.
Results
FOXA1 Loss Is an Independent Predictor of Decreased
Overall Survival in Humans with Bladder Cancer
Clinicopathologic characteristics of the tumors represented
on the TMA are listed in Table 1. Primary histological tumor
types for the 301 patients in our study included 278 pure UCs
(92%) and 23 UCs with squamous differentiation (8%). Four
patients (1%) were treated with neoadjuvant chemotherapy.
At the time of last follow-up, there were 139 deaths (59%).
Median follow-up was 15.1 months (interquartile range, 5.6
to 29.7) for censored patients. Median overall survival
duration was 42.1 months (95% CI, 27.4e58.4 months), with
a 5-year actuarial estimated overall survival rate of 42.3%ajp.amjpathol.org - The American Journal of Pathology
Figure 2 UBC-Cre/ERT2 efﬁciently ablates Foxa1 expression in the urothelium after tamoxifen injection. Control Foxa1loxp/loxp mice and experimental UBC-
Cre/ERT2/Foxa1loxp/loxp mice were injected with 1 mg per day of tamoxifen for 5 days and euthanized. Tissue was then prepared as described in Materials and
Methods for histological analysis to assess the effect of short-term Foxa1 knockout. Hematoxylin and eosin (H&E), FOXA1, uroplakin III (UPKIII), and bro-
modeoxyuridine (BrdU) staining of bladders dissected from tamoxifen-injected Foxa1loxp/loxp (AeD) and UBC-Cre/ERT2/Foxa1loxp/loxp (EeH) mice. There are no
signiﬁcant histological changes after Foxa1 knockout (A and E). Although Foxa1 expression is detected in the urothelium of control Foxa1ﬂox/ﬂox mice (B), it is
absent in the urothelium of tamoxifen-injected UBC-Cre/ERT2/Foxa1loxp/loxp bladders (F). Expression of the terminal marker of urothelial differentiation UPKIII
is detected in both tamoxifen-injected control Foxa1loxp/loxp bladders (C), as well as in tamoxifen-injected UBC-Cre/ERT2/Foxa1loxp/loxp urothelium (G). Both
Foxa1loxp/loxp mice and UBC-Cre/ERT2/Foxa1loxp/loxp mice bladders do not exhibit urothelial proliferation as shown by BrdU staining (D and H, respectively).
FOXA1 and Bladder Cancer Prognosis(95%CI, 35.6%e48.8%). Conﬁrming our previous ﬁnding in
an independent cohort,10 FOXA1 expression was inversely
correlated with increasing tumor stage by Spearman rank
correlation (P< 0.001; rZ0.38; nZ 234). We compared
the overall survival of patients with low versus high FOXA1
expression. For survival analysis, IHC scores were dichoto-
mized as low or high expression using the median (5.5) as a
cutoff value, with values at the median grouped into the high
expression category. Low FOXA1 expression was associated
with shorter overall survival on univariate log rank analysis
(P < 0.001) (Figure 1). Median overall survival for low
versus high FOXA1 expression was 22.1 months (95% CI,
16.5e31.9 months) and 68 months (95% CI, 48.2 months to
not reached), respectively. Other variables associated with
overall survival on univariate analysis include patient age
(P < 0.001), Charlson comorbidity index (P < 0.001), and
tumor stage (P< 0.001). Sex (PZ 0.061) was also included
in the multivariate model. After controlling for patient age,
tumor stage, sex, and Charlson comorbidity index score, high
FOXA1 expression is an independent predictor of higher
overall survival (Table 2).
UBC-Cre/ERT2 System Is Sufﬁcient to Induce Foxa1
Knockout in Murine Urothelium
To determine the phenotypic effect of genetically ablating
Foxa1 expression in murine urothelium, we initiated a breeding
program consisting of a tamoxifen-inducible Cre recombinase
driven by the ubiquitin promoter (UBC-Cre/ERT2) and our
Foxa1loxp/loxpmice, resulting in the creation ofUBC-Cre/ERT2/
Foxa1loxp/loxp mice. Littermate control Foxa1loxp/loxp mice and
experimental UBC-Cre/ERT2/Foxa1loxp/loxpmice were injected
with tamoxifen for 5 days and then separated into 3 differentThe American Journal of Pathology - ajp.amjpathol.orggroups (Materials and Methods). Histomorphometric analysis
of control Foxa1loxp/loxp mice (Figure 2A) and experimental
UBC-Cre/ERT2/Foxa1loxp/loxpmice (Figure 2E) after tamoxifen
injection for 5 days (Figure 2E) revealed no obvious differences
in tissue architecture, whereas IHC analysis ofUBC-Cre/ERT2/
Foxa1loxp/loxp mice revealed efﬁcient and widespread ablation
of urothelial Foxa1 expression; however, control Foxa1loxp/loxp
mice retained Foxa1 expression (Figure 2, B and F). Both
tamoxifen-treated Foxa1loxp/loxp mice and tamoxifen-treated
experimental UBC-Cre/ERT2/Foxa1loxp/loxp expressed UpkIII
(Figure 2, C and G), a marker of urothelial differentiation, and
were quiescent in regard to proliferation (Figure 2, D and H).
These results indicate that the UBC-Cre/ERT2 system
efﬁciently ablates Foxa1 expression in the urothelium of
adult mice.
Sexually Dimorphic Histological Phenotypes of Foxa1
Knockout Murine Urothelium
Bladder tissue dissected from tamoxifen-injected, genetic
control Foxa1loxp/loxpmice exhibited typical murine urothelial
morphology, consisting of a superﬁcial umbrella cell layer
and a single layer each of intermediate and basal cells
(Figure 3A). Bladder tissue dissected from male UBC-Cre/
ERT2/Foxa1loxp/loxp mice obtained 3 months after tamoxifen
injection revealed basal cell hyperplasia (Figure 3B) and
degenerative vacuoles within the umbrella cell layer
(Figure 3B). The presence of urothelial hyperplasia was also
detected 6 months after tamoxifen-induced Foxa1 knockout
(Figure 3, C and D). Nine of the 10 male Foxa1 knockout
mice developed urothelial hyperplasia, and the other mouse
developed squamous metaplasia. Importantly, urothelial hy-
perplasia was signiﬁcantly associated with Foxa1 knockout in1389
Figure 3 Foxa1 knockout results in hyperplasia in male mice and kera-
tinizing squamous metaplasia in female mice. A: Hematoxylin and eosin
(H&E) of control Foxa1loxp/loxpmale mice (6 months after tamoxifen injection)
reveals a single layer of superﬁcial umbrella cells and a single layer of in-
termediate and basal urothelium (inset). B: Analysis of bladder tissue
dissected from male UBC-Cre/ERT2/Foxa1loxp/loxp mice 3 months after
tamoxifen injection reveals the presence of degenerative vacuoles (inset,
bottom left) and basal hyperplasia (inset, bottom right) of urothelium. C
and D: Basal cell hyperplasia is also present in bladder tissue dissected from
male UBC-Cre/ERT2/Foxa1loxp/loxp mice 6 months after tamoxifen injection.
The insets show basal cell hyperplasia. E: Histological analysis of female
control Foxa1loxp/loxp male mice (6 months after tamoxifen-injection) reveals
urothelial morphologic ﬁndings identical to those of male mice, typical of
normal bladder tissue. Inset shows normal bladder urothelium. F: Analysis of
bladder tissue dissected from female UBC-Cre/ERT2/Foxa1loxp/loxp mice 3
months after tamoxifen injection reveals presence of degenerative vacuoles
(inset) similar to those observed in male UBC-Cre/ERT2/Foxa1loxp/loxp mice. G
and H: However, we also detected keratinizing squamous metaplasia in fe-
male UBC-Cre/ERT2/Foxa1loxp/loxp mice 3 months and 6 months after tamox-
ifen injection, with hyperkeratinization (inset and H). Scale bars: 25 mm.
Reddy et almale mice (P< 0.0005; Fisher’s exact test). We did not detect
hyperplasia in any Foxa1loxp/loxp control male mice after
tamoxifen injection.
Bladder tissue dissected from female Foxa1loxp/loxp con-
trol mice (Figure 3E) 6 months after tamoxifen injection1390appeared identical to that dissected from male Foxa1loxp/loxp
control mice. Moreover, analysis of bladder tissue dissected
from female UBC-Cre/ERT2/Foxa1loxp/loxp mice obtained 3
months after tamoxifen injection revealed the appearance of
degenerative vacuoles within the umbrella cell layer
(Figure 3F) similar to those observed in the male mice at 3
months (Figure 3B).
Phenotypic alterations consistent with KSM were
observed in female UBC-Cre/ERT2/Foxa1loxp/loxp mice after
FOXA1 knockout 3 and 6 months after tamoxifen injection
(Figure 3, G and H). Seven of 10 female Foxa1 knockout
mice developed squamous metaplasia, and one other mouse
exhibited areas of cellular hyperplasia. As was the case with
urothelial hyperplasia in male Foxa1 knockout mice, Foxa1
knockout in female mice was signiﬁcantly associated with
squamous differentiation (P Z 0.001; Fisher’s exact test).
These results indicate that Foxa1 expression is required to
maintain normal differentiation of urothelium in male and
female mice, and genetic ablation of Foxa1 in the urothe-
lium has sex-speciﬁc effects on urothelial differentiation.
Microarray Analysis Reveals Sex-Speciﬁc Alterations in
Gene Expression after Foxa1 Knockout
We performed microarray analysis to conﬁrm the sex-
dependent nature of the histological phenotypes observed
after Foxa1 knockout in UBC-Cre/ERT2/Foxa1loxp/loxp mice.
In addition, we used this approach to identify the most
signiﬁcantly up-regulated genes after Foxa1 ablation in male
and female mice. Microarray analysis and separation of data
by sex (Supplemental Tables S1eS3) revealed a heteroge-
neous list of up-regulated genes in male UBC-Cre/ERT2/
Foxa1loxp/loxp mice, including alterations in the expression of
tumor suppressors and various transcription factors (Table 3).
On the other hand, 6 of the 10 most overexpressed genes in
female UBC-Cre/ERT2/Foxa1loxp/loxp mice compared with
control Foxa1loxp/loxp mice have been previously associated
with keratinocyte differentiation, including Ck14,20 Krt6a/
Ck6a,21 Lipk,22 Sprr2F,23 Dsg,24 and Krt10/Ck1025
(Table 3). These ﬁndings are consistent with histological
evidence of KSM (Figure 3, G and H) and previous reports
of an association between FOXA1 loss and squamous
differentiation in humans.10,12,13
We next used IPA to further analyze the microarray data
to identify networks and pathways speciﬁcally affected by
Foxa1 knockout in male and female bladder tissue that may
potentially be altered in human disease. In male Foxa1
knockout bladders, the top network identiﬁed was inﬂam-
matory disease, inﬂammatory response, and cell cycle. This
pathway consists of several different genes that may play
important roles in human bladder disease in the context of
FOXA1 inactivation. For example, genes whose expression
is associated with inﬂammation included Clec4d and
Clec4e, Nos2, S100a8, Saa3, and Reg3g, a bactericidal
lectin (Supplemental Figure S1). In addition, IPA identiﬁed
a potential role for Dmbt1, Kap, Retnla/b, and Serpine1,ajp.amjpathol.org - The American Journal of Pathology
Table 3 List of Signiﬁcantly Up-Regulated Genes After Foxa1
Knockout in Male and Female Mice
Male Foxa1 knockout Female Foxa1 knockout
Gene
Log fold
change P value Gene
Log fold
change P value
Ldoc1 3.95 0.003008 Krt14 2.41 0.002304
Lypd5 3.76 0.001831 Krt6a 2.11 0.071096
Ighg3 2.09 0.005952 Lipk 2.09 0.001091
Retnla 2.06 0.092382 Sprr2f 2.05 0.018622
Dmbt1 2.00 0.034411 Dsg3 1.84 0.035792
Kap 1.96 0.000547 Ppbp 1.78 0.076981
Sdr16c6 1.88 0.008045 Krt10 1.58 0.00112
Lipk 1.82 0.095307 Skint3 1.57 0.022924
Mup4 1.53 0.000946 Calcb 1.49 0.074217
Anxa9 1.51 0.037675 Ephx3 2.76 0.000339
FOXA1 and Bladder Cancer Prognosiswhich are all implicated in tumorigenesis. We then used the
Upstream Analysis function in IPA to identify potential
transcriptional regulators activated by Foxa1 knockout in
male bladders (Supplemental Figure S2). Among these
transcriptional regulators was CTNNB1/b-catenin, which
has been recently linked to bladder tumorigenesis in male
mice,26 suggesting a potential mechanism whereby loss of
FOXA1 drives activation of b-catenin during male bladder
tumorigenesis.Figure 4 Foxa1 knockout results in increased urothelial proliferation and alter
yuridine (BrdU) (B), cytokeratin 14 (Ck14) (C), cytokeratin 10 (Ck10) (D), and uroplak
injection reveals normal expression patterns. Immunostaining of Foxa1 (F), BrdU (G)
months after tamoxifen injection shows that Foxa1 knockout activates urothelial prol
basal expression pattern of Ck14 after FOXA1 knockout. Immunostaining of Foxa1 (K
mice 6months after tamoxifen injection shows an expression pattern identical tomal
UpkIII (T) in female UBC-Cre/ERT2/Foxa1loxp/loxp mice 6 months after tamoxifen inj
(inset and Q) and expansion of Ck14 and Ck10 expressing urothelial cells. In add
expression. P, inset: Retention of Foxa1 expression in small subset of superﬁcial u
The American Journal of Pathology - ajp.amjpathol.orgIPA analysis of female bladder microarray results identiﬁed
cellular growth and proliferation, tissue development, and in-
ﬂammatory response as the top disease network associated with
Foxa1 knockout. Another disease network associated with
Foxa1 knockout in female bladders included dermatological
diseases (DSG, KRT10, KRT14, and KRT6A). This correlates
well with the observed histological alterations after Foxa1
knockout in female mice (Supplemental Figure S3). We next
performed Upstream Analysis to identify potential transcrip-
tional regulators, which may additionally contribute to alter-
ations in gene expression after Foxa1 knockout in female
bladders, focusing on Krt14 and Krt10 because these keratins
are implicated in human bladder cancer27e29 and associated
with Foxa1/FOXA1 inactivation in murine and human
tumors.30 Upstream analysis suggested Tp63 activation of
Krt14, which has been previously implicated in bladder
development and malignancy,31,32 as being potential factors
associatedwith altered gene expression afterFoxa1 knockout in
female mice (Supplemental Figure S4). In addition, upstream
pathway analysis suggested that the activation of MDM2 and
RBL1 may be in part responsible for increased expression of
Krt10. In summary, IPM analysis identiﬁed several interesting
avenues for future studies.
IHC performed on tissue dissected from Foxa1loxp/loxp
(Figure 4, A and K) and UBC-Cre/ERT2/Foxa1loxp/loxp
(Figure 4, F and P) conﬁrmed that Foxa1 knockout wasations in cytokeratin expression. Immunostaining of Foxa1 (A), bromodeox-
in III (UpkIII) (E) in male control Foxa1loxp/loxpmice 6months after tamoxifen
, Ck14 (H), Ck10 (I), and UpkIII (J) in male UBC-Cre/ERT2/Foxa1loxp/loxpmice 6
iferation and expansion of Ck14 and Ck10 expression. The inset inH shows the
), BrdU (L), Ck14 (M), Ck10 (N), and UpkIII (O) in female control Foxa1loxp/loxp
emice (AeE). Immunostaining of Foxa1 (P), BrdU (Q), Ck14 (R), Ck10 (S), and
ection shows that Foxa1 knockout activates basal urothelial cell proliferation
ition, areas of keratinizing squamous metaplasia were negative for UpkIII
rothelium. R, inset: Foxa1þ superﬁcial urothelium are Ck14.
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Table 4 Correlation of Immunohistochemical Scores for FOXA1
with Cytokeratin (CK)14 and CK10 in Human Cystectomy Samples
CK r P value n
CK14 0.35 <0.001 446
CK10 0.04 0.429 427
Figure 5 In humans, absence of FOXA1 expression is signiﬁcantly asso-
ciatedwith increased cytokeratin 14 (CK14) expression, independent of tumor
stage. Representative immunostaining of human benign and tumor tissue
microarray bladder tissue samples for FOXA1 and CK14. Scale bars: 100 mm.
Reddy et almaintained 6 months after tamoxifen injection. In keeping
with histological evidence of urothelial hyperplasia in male
Foxa1 knockout mice and KSM in female Foxa1 knockout
mice, urothelium in Foxa1 knockout bladders was prolif-
erative by BrdU staining (Figure 4, B, G, L, and Q).
Interestingly, BrdU staining was concentrated within the
basal cell layer of the urothelium in female UBC-Cre/ERT2/
Foxa1loxp/loxp tissue (Figure 4Q).
Normally, Ck14 expression is extremely low in murine
urothelium (Figure 4, C and M). However, Foxa1 knockout
resulted in an expansion of the Ck14-positive cell population
in the basal layer of male UBC-Cre/ERT2/Foxa1loxp/loxp mice
(Figure 4H) and a remarkable expansion of Ck14-positive
cells throughout the urothelium in female UBC-Cre/ERT2/
Foxa1loxp/loxp bladder tissue (Figure 4R), conﬁrming our
microarray results.
Ck10 protein is not detected in normal urothelium
(Figure 4, D and N) but was expanded in male UB-Cre/ERT2/
Foxa1loxp/loxp bladder tissue (Figure 4I) and was detected at
even greater levels in the urothelium of female UBC-Cre/
ERT2/Foxa1loxp/loxp mice (Figure 4S), also consistent with our
microarray results.
The terminal differentiation marker UpkIII is normally
detected in murine urothelium (Figure 4, E and O) and was
similarly present in the urothelium of male UBC-Cre/ERT2/
Foxa1loxp/loxp bladders (Figure 4J). However, areas of squa-
mous differentiation in the urothelium of female UBC-Cre/
ERT2/Foxa1loxp/loxp bladders exhibited a loss of UpkIII
expression (Figure 4T), consistent with the development of
KSM.33 These results conﬁrm thatFoxa1 expression is required
for the maintenance of a differentiated phenotype in the uro-
thelium and that genetic ablation of Foxa1 results in sexually
dimorphic phenotypes. Because FOXA1 loss is common in
human UBC, increases in CK14 expression after FOXA1
knockout suggested that a similar relationship may exist in
human UBC.
In Agreement with Knockout Mouse Studies, FOXA1
Loss Is Associated with High CK14 Expression in
Human Bladder Cancer Specimens
Increased CK14 expression has been reported in human
UBC.11,34 In addition, basal UBC tumors express high CK14
levels, as well as diminished FOXA1 expression.12 Our studies
indicate that ablation of Foxa1 expression is strongly associated
with increased Ck14 expression throughout the bladder
epithelium in female Foxa1 knockout mice and enriched in the
basal urothelium ofmaleFoxa1 knockoutmice. In keepingwith
these observations, we used the human UBC cohort to1392determine whether the relationship between these markers
extended to human disease. Interestingly, the prevalence of
CK14 expression was more often seen in FOXA1-negative
human bladder tumors (44%) compared with FOXA1-positive
tumors (17%) (Spearman’s test; Table 4 and Figure 5). On the
other hand, CK10 expression in human FOXA1-negative and
FOXA1-positive tumors was similar (24% versus 31%)
(Spearman’s test; data not shown). However, because FOXA1
expression is decreased and CK14 expression is increased with
advancing tumor stage, we tested whether tumor stage was
confounding the association between FOXA1 loss and CK14
gain. Implementation of the extended Mantel-Haenszel test-
stratifying groups by tumor stage revealed that the association
between decreased FOXA1 expression and increased CK14
expression is statistically signiﬁcant (PZ 0.004), independent
of tumor stage. These results conﬁrm a signiﬁcant association
between FOXA1 loss and CK14 gain in human UBC, ﬁrst
identiﬁed in our mouse model, and subsequently validated in
our patient cohort, independent of tumor stage.
Discussion
Building on ﬁndings from our previous studies,10,13 as well as
a recent study by the Cancer Genome Atlas11 and others,12
indicating that the loss of FOXA1 expression is a common
event in human bladder cancers, we now report that decreased
FOXA1 expression is an independent predictor of clinical
outcome in UBC (Figure 1 and Table 2). Increasing evidence
suggests that deregulation of FOX transcription factors is
associated with neoplastic transformation and progression in a
variety of malignant tumors.
Previously, we found that FOXA1 loss is associated with
high-grade, late-stage UBC, as well as the aggressive pheno-
typic behavior typical of advanced UBC.10 To determine the
prognostic signiﬁcance of FOXA1 loss in clinical samples, we
created a clinically annotated TMA of UBC samples fromajp.amjpathol.org - The American Journal of Pathology
FOXA1 and Bladder Cancer Prognosispatients who underwent radical cystectomy. In addition to
verifying our initial ﬁndings with a separate cohort from our
institution, we determined that retention of FOXA1 expression
is associated with improved overall survival on multivariate
analysis after controlling for tumor stage, patient age, sex, and
comorbidity status. This is the ﬁrst report indicating that the
decreased FOXA1 expression is independently associated with
lower overall survival of UBC patients. The survival analysis
performed here was limited in that recurrence-free and disease-
speciﬁc survival could not be assessed because of the rela-
tively low number of events (nZ 39 for recurrence and nZ 8
for UBC-speciﬁc deaths). In this study, we sought to examine
tumor biology independent of the effects of systemic chemo-
therapy. Therefore, the TMA was speciﬁcally constructed to
exclude those who underwent neoadjuvant chemotherapy.
Because neoadjuvant therapy is now often used in the man-
agement of muscle-invasive bladder cancer to treat presumed
micrometastases, future studies are needed to assess whether
neoadjuvant chemotherapy alters the expression of FOXA1 or
if its expression predicts response to chemotherapy.35
In our animal studies, Foxa1 knockout resulted in hyper-
plasia in male mice and KSM in female mice. These results
offer further evidence that expression of Foxa1 is required to
maintain differentiation of the urothelium, much as is the case
for prostate epithelium.36 Men are at higher risk for developing
UBC, and increased incidence of UBC among men has been
historically attributed to higher rates of smoking and industrial
exposure to carcinogens. As these epidemiological distinctions
have subsided, there has been increased interest in determining
the role of sex steroid receptors (and circulating sex steroids) in
UBC incidence and progression. For instance, androgen re-
ceptor knockout prevented carcinogen-induced UBC in male
and female mice, as did androgen deprivation.37 Moreover,
knockout of estrogen receptor-a and estrogen receptor-b
reportedly affects bladder tumorigenesis after carcinogen
exposure.38,39 Both FOXA1 and FOXA2 physically interact
with the androgen receptor,40,41 and FOXA1 interacts with
estrogen receptor-a. Interestingly, genetic ablation of both
Foxa1 and Foxa2 in the liver of mice reverses the sex differ-
ences in carcinogen-induced hepatocellular carcinoma.42 The
ability of FOXA1 to interact with steroid receptors and its
ability to modulate carcinogenesis in male versus female mice
suggests in liver and now bladder a role for FOXA1 in sex-
associated differences in UBC. However, forced over-
expression of androgen receptor and estrogen receptors in the
presence and absence of FOXA1 and steroid treatment in
human bladder cancer cell lines did not result in detectable al-
terations in gene expression patterns similar to those observed
in the in vivo experiments (data not shown). These ﬁndingsmay
suggest that additional transcription factors and/or epigenetic
alterations are active in sex-speciﬁc bladder tumorigenesis after
inactivation of Foxa1 in mice and FOXA1 in humans. In
addition to interacting with sex steroid receptors, we recently
reported that FOXA1 interacts with the nuclear factor one
family of transcription factors.43 Future identiﬁcation of novel
FOXA1-interacting proteins important for bladder cancer willThe American Journal of Pathology - ajp.amjpathol.orgreveal important insights into themolecular pathogenesis of this
common malignant neoplasm.
This study also conﬁrmed a strong association between the
absence of FOXA1 expression and increased CK14 levels in
human UBC. An association between FOXA1 and CK14 in
basal and squamous UBC was recently found by molecular
subtyping studies of the Cancer Genome Atlas and by
others.11,12 In addition, markers for these proteins have been
suggested to be useful for the identiﬁcation of speciﬁcmolecular
subtypes of UBC.30 This pattern was also mirrored after Foxa1
knockout in the bladders of mice and suggests that this model is
appropriate for future studies regarding the relationship between
FOXA1 and CK14 expression in human UBC. Volkmer et al44
recently found that a cell population enriched for high CK14
expression is capable of causing various differentiation states
present in UBC tumors, suggesting that the tumor cell of origin
modelmay apply toUBC.Moreover,Volkmer et al44 also found
that increased CK14 is associated with worse overall survival in
UBC, as well as increased tumor recurrence and progression of
pTa tumors. Although we did not ﬁnd signiﬁcant associations
between CK14 expression and overall survival (data not
shown), we observed that CK14 expressionwas associatedwith
increasing tumor stage. Because increased CK14 is potentially
associated with a tumor-initiating cell phenotype in UBC, and
we found that FOXA1 loss is associated with the aggressive
phenotype attributed to UBC,10 diminished FOXA1 expression
may also be associated with this molecular phenotype. Future
mechanistic studies will focus on the relationship between
FOXA1 loss and increased CK14 in UBC.
In summary, our results indicate that loss of FOXA1
expression is an independent adverse predictor of overall
survival in UBC. In addition, we found that abrogation of
Foxa1 in mice results in sexually dimorphic histological
alterations and an increase in the expression of Ck14, which is
also associated with decreased FOXA1 expression in humans.
These results provide further evidence of an important role of
FOXA1 in human UBC progression and clinical outcome and
provide important insight into the potential role of forkhead
family members in the sexual dimorphic nature of UBC in
regard to incidence and disease progression.
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